Nature Biotechnology: Mount Sinai Breakthrough Enables Precision Control of mRNA Vaccine Cell Targeting

On April 29, 2026, researchers at the Icahn School of Medicine at Mount Sinai published a landmark study in Nature Biotechnology describing a new technology that challenges fundamental assumptions about mRNA vaccine mechanisms and provides a method to control which specific cell types express mRNA vaccine cargo. The research demonstrated that dendritic cell expression — long assumed to be the key driver of mRNA vaccine immunogenicity — is not strictly required for efficacy, and that directing mRNA expression to other immune cell populations can actually enhance or modulate immune responses in therapeutically useful ways. The technology opens two major new avenues: (1) amplifying anti-tumor immune responses for mRNA cancer vaccines by directing expression toward cells that maximize T-cell priming, and (2) dampening autoimmune responses by directing tolerogenic mRNA toward regulatory pathways. The platform uses modified lipid nanoparticle formulations with cell-type-specific targeting ligands, building on the LNP delivery technology underlying all approved mRNA vaccines.